<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320255</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-027</org_study_id>
    <nct_id>NCT00320255</nct_id>
  </id_info>
  <brief_title>A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether apixaban is well-tolerated and acceptable as
      anticoagulant therapy, when administered to patients with advanced or metastatic cancer and
      at increased risk for venous thromboembolic events. Demonstration of a favorable benefit:risk
      profile could lead to significant reduction in this serious and sometimes fatal complication
      of ongoing cancer and its treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Composite of Confirmed Major Bleeding and Clinically Relevant Nonmajor (CRNM) Bleeding</measure>
    <time_frame>From first dose to 2 days following last dose of study drug</time_frame>
    <description>Major bleeding was defined as clinically overt bleeding accompanied by 1 or more of the following:
A decrease in hemoglobin of 20 g/L or more or
Required transfusion of 2 or more units of packed red blood cells or whole blood, or
Occurred in a critical site
Contributed to death.
CRNM bleeding was defined as bleeding that did not meet the criteria for major bleeding but that, in routine clinical practice, would be considered relevant and not trivial by a patient and physician. Such bleeding satisfied a priori criteria defined by the ICAC, including:
Skin hematoma
Epistaxis that lasted for longer than 5 minutes, was repetitive, or led to an intervention
Hematuria that was macroscopic and either spontaneous or lasted for longer than 24 hours after instrumentation of the urogenital tract
Any other bleeding type that was considered to have clinical consequences.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of Venous Thromboembolism (VTE) and All-cause Death</measure>
    <time_frame>First dose to 2 days following last dose of study drug</time_frame>
    <description>VTE includes symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE). Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism (PE), and All-cause Death</measure>
    <time_frame>First dose to 30 days following last dose of study drug</time_frame>
    <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments (popliteal vein or higher) of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan (nonhigh probability) with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of Venous Thromboembolism (VTE) and VTE-related Death</measure>
    <time_frame>First dose to 2 days following last dose of study drug</time_frame>
    <description>VTE includes symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE). Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite of Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism (PE), and Venous Thromboembolism (VTE)-Related Death</measure>
    <time_frame>First dose to 2 days following last dose of study drug</time_frame>
    <description>VTE includes symptomatic DVT and PE. Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-Cause Death</measure>
    <time_frame>First dose to 2 days following last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pulmonary Embolism (Fatal or Nonfatal)</measure>
    <time_frame>First dose to 2 days following last dose of study drug</time_frame>
    <description>Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels of greater than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Nonfatal Pulmonary Embolism</measure>
    <time_frame>First dose to 2 days following last dose of study drug</time_frame>
    <description>Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Deep Vein Thrombosis</measure>
    <time_frame>First dose to 2 days following last dose of study drug</time_frame>
    <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Distal Deep Vein Thrombosis</measure>
    <time_frame>First dose to 2 days following last dose of study drug</time_frame>
    <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Proximal Deep Vein Thrombosis</measure>
    <time_frame>First dose to 2 days following last dose of study drug</time_frame>
    <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died and With Adverse Events (AEs), Serious Adverse Events (SAEs), Bleeding AEs, and Discontinuations Due to AEs</measure>
    <time_frame>First dose to 2 days following last dose of study drug</time_frame>
    <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Thrombosis</condition>
  <condition>Cancer</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Apixaban, 5 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received apixaban as tablet, 5 mg, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Apixaban, 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received apixaban as tablet, 10 mg, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Apixaban, 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received apixaban as tablet, 20 mg, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Apixaban, 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Oral tablets administered once daily in 5-, 10-, or 20-mg dose</description>
    <arm_group_label>Cohort 1: Apixaban, 5 mg</arm_group_label>
    <arm_group_label>Cohort 1: Apixaban, 10 mg</arm_group_label>
    <arm_group_label>Cohort 1: Apixaban, 20 mg</arm_group_label>
    <arm_group_label>Cohort 2: Apixaban, 5 mg</arm_group_label>
    <other_name>BMS-562247</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets administered once daily</description>
    <arm_group_label>Cohort 1: Placebo</arm_group_label>
    <arm_group_label>Cohort 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Recipients of either first- or second-line chemotherapy for advanced or metastatic
             lung, breast, gastrointestinal, bladder, ovarian, or prostate cancer or myeloma,
             selected lymphomas, or cancer of unknown origin

          -  Able to begin study medication ≤6 weeks of starting either first- or second-line
             chemotherapy.

          -  Expected course of chemotherapy must have been ≥ 90 days after the start of
             chemotherapy

          -  Per Protocol Amendment 5, patients receiving bevacizumab were eligible to participate,
             provided that bevacizumab was used for indications approved by local country law

        Key Exclusion Criteria:

          -  Women who are pregnant, breastfeeding

          -  History of deep vein thrombosis or pulmonary embolism

          -  Active bleeding or at high risk of bleeding

          -  Metastatic brain cancer

          -  Familial bleeding diathesis

          -  Serious hemorrhage requiring hospitalization, transfusion, or surgical intervention
             within 4 weeks of study entry

          -  Expected survival &lt;6 months or an Eastern Cooperative Oncology Group performance
             status ≥3.

          -  Candidates for bone marrow transplantation within the 12-week treatment period or
             30-day follow-up period

          -  Uncontrolled hypertension (systolic blood pressure &gt;200 mm Hg and/or diastolic blood
             pressure &gt;110 mm Hg

          -  Coagulopathy (international normalized ratio &gt;1.5 or platelet count &lt;100*10^9/L) if
             not yet receiving chemotherapy or &lt;50*10^9/L if receiving chemotherapy). Platelet
             count must have been &gt;100*10^9/L before starting study medication

          -  One or more of the following: alanine aminotransferase &gt;3 times the upper limit of
             normal (ULN), total bilirubin &gt;2*ULN, or calculated creatinine clearance &lt;30 mL/min.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Of Southern Calif. /Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Inst</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School Of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Texas Md Anderson Cancer Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 2C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2006</study_first_submitted>
  <study_first_submitted_qc>May 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <results_first_submitted>March 14, 2016</results_first_submitted>
  <results_first_submitted_qc>August 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 16, 2016</results_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anticoagulant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 130 participants were enrolled and randomized; however, 1 withdrew consent and 2 no longer met study criteria. Therefore, 127 participants were treated. Reasons Not Completed listed in the data table below were summarized for 127 participants who received treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Placebo</title>
          <description>Participants received placebo tablets once daily</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: Apixaban, 5 mg</title>
          <description>Participants received apixaban as tablet, 5 mg, once daily</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1: Apixaban, 10 mg</title>
          <description>Participants received apixaban as tablet, 10 mg, once daily</description>
        </group>
        <group group_id="P4">
          <title>Cohort 1: Apixaban, 20 mg</title>
          <description>Participants received apixaban as tablet, 20 mg, once daily</description>
        </group>
        <group group_id="P5">
          <title>Cohort 2: Placebo</title>
          <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 2: Apixaban, 5 mg</title>
          <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance/noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who were randomized to receive treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Placebo</title>
          <description>Participants received placebo tablets once daily</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1: Apixaban, 5 mg</title>
          <description>Participants received apixaban as tablet, 5 mg, once daily</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1: Apixaban, 10 mg</title>
          <description>Participants received apixaban as tablet, 10 mg, once daily</description>
        </group>
        <group group_id="B4">
          <title>Cohort 1: Apixaban, 20 mg</title>
          <description>Participants received apixaban as tablet, 20 mg, once daily</description>
        </group>
        <group group_id="B5">
          <title>Cohort 2: Placebo</title>
          <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 2: Apixaban, 5 mg</title>
          <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="2"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Younger than 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 years and older but younger than 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 years and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of Venous Thromboembolism (VTE) and All-cause Death</title>
        <description>VTE includes symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE). Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
        <time_frame>First dose to 2 days following last dose of study drug</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixaban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Venous Thromboembolism (VTE) and All-cause Death</title>
          <description>VTE includes symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE). Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3.9" upper_limit="31.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O5" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                    <measurement group_id="O6" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism (PE), and All-cause Death</title>
        <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments (popliteal vein or higher) of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan (nonhigh probability) with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
        <time_frame>First dose to 30 days following last dose of study drug</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixaban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism (PE), and All-cause Death</title>
          <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments (popliteal vein or higher) of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan (nonhigh probability) with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2.2" upper_limit="27.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O5" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                    <measurement group_id="O6" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of Venous Thromboembolism (VTE) and VTE-related Death</title>
        <description>VTE includes symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE). Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
        <time_frame>First dose to 2 days following last dose of study drug</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixaban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Venous Thromboembolism (VTE) and VTE-related Death</title>
          <description>VTE includes symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE). Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3.9" upper_limit="31.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O5" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                    <measurement group_id="O6" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite of Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism (PE), and Venous Thromboembolism (VTE)-Related Death</title>
        <description>VTE includes symptomatic DVT and PE. Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
        <time_frame>First dose to 2 days following last dose of study drug</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixaban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism (PE), and Venous Thromboembolism (VTE)-Related Death</title>
          <description>VTE includes symptomatic DVT and PE. Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.
Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2.2" upper_limit="27.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O5" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                    <measurement group_id="O6" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-Cause Death</title>
        <time_frame>First dose to 2 days following last dose of study drug</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixaban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-Cause Death</title>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O5" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                    <measurement group_id="O6" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pulmonary Embolism (Fatal or Nonfatal)</title>
        <description>Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels of greater than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
        <time_frame>First dose to 2 days following last dose of study drug</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixiban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pulmonary Embolism (Fatal or Nonfatal)</title>
          <description>Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels of greater than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O5" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                    <measurement group_id="O6" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Nonfatal Pulmonary Embolism</title>
        <description>Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
        <time_frame>First dose to 2 days following last dose of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixaban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Nonfatal Pulmonary Embolism</title>
          <description>Any 1 of the following was considered diagnostic for PE:
Constant intraluminal filling defects in 2 or more views on pulmonary angiography
Sudden contrast cutoff of 1 or more vessels more than 2.5 mm in diameter on a pulmonary angiogram
A high probability VQ lung scan showing 1 or more segmental perfusion defects with corresponding normal ventilation (mismatch defect)
An abnormal VQ lung scan with satisfaction of either criterion 1 or 2
Abnormal spiral computed tomography scan showing thrombus in pulmonary vessels.</description>
          <units>Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O5" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                    <measurement group_id="O6" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Deep Vein Thrombosis</title>
        <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.</description>
        <time_frame>First dose to 2 days following last dose of study drug</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixaban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Deep Vein Thrombosis</title>
          <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3.9" upper_limit="31.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O5" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                    <measurement group_id="O6" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Distal Deep Vein Thrombosis</title>
        <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.</description>
        <time_frame>First dose to 2 days following last dose of study drug</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixaban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Distal Deep Vein Thrombosis</title>
          <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O5" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                    <measurement group_id="O6" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Proximal Deep Vein Thrombosis</title>
        <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.</description>
        <time_frame>First dose to 2 days following last dose of study drug</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixaban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Proximal Deep Vein Thrombosis</title>
          <description>Any 1 of the following was considered diagnostic for DVT:
New or previously undocumented noncompressibility of 1 or more proximal venous segments of the legs on CUS
Constant intraluminal filling defects on 2 or more views on contrast venography in 1 or more venous segments in the legs or pelvis or involving the inferior vena cava.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2.2" upper_limit="27.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O5" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                    <measurement group_id="O6" value="0">No statistical analyses were conducted for Cohort 2.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died and With Adverse Events (AEs), Serious Adverse Events (SAEs), Bleeding AEs, and Discontinuations Due to AEs</title>
        <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
        <time_frame>First dose to 2 days following last dose of study drug</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixaban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died and With Adverse Events (AEs), Serious Adverse Events (SAEs), Bleeding AEs, and Discontinuations Due to AEs</title>
          <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite of Confirmed Major Bleeding and Clinically Relevant Nonmajor (CRNM) Bleeding</title>
        <description>Major bleeding was defined as clinically overt bleeding accompanied by 1 or more of the following:
A decrease in hemoglobin of 20 g/L or more or
Required transfusion of 2 or more units of packed red blood cells or whole blood, or
Occurred in a critical site
Contributed to death.
CRNM bleeding was defined as bleeding that did not meet the criteria for major bleeding but that, in routine clinical practice, would be considered relevant and not trivial by a patient and physician. Such bleeding satisfied a priori criteria defined by the ICAC, including:
Skin hematoma
Epistaxis that lasted for longer than 5 minutes, was repetitive, or led to an intervention
Hematuria that was macroscopic and either spontaneous or lasted for longer than 24 hours after instrumentation of the urogenital tract
Any other bleeding type that was considered to have clinical consequences.</description>
        <time_frame>From first dose to 2 days following last dose of study drug</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo</title>
            <description>Participants received placebo tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Apixaban, 5 mg</title>
            <description>Participants received apixaban as tablet, 5 mg, once daily</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Apixaban, 10 mg</title>
            <description>Participants received apixaban as tablet, 10 mg, once daily</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: Apixaban, 20 mg</title>
            <description>Participants received apixaban as tablet, 20 mg, once daily</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Placebo</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Apixaban, 5 mg</title>
            <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Confirmed Major Bleeding and Clinically Relevant Nonmajor (CRNM) Bleeding</title>
          <description>Major bleeding was defined as clinically overt bleeding accompanied by 1 or more of the following:
A decrease in hemoglobin of 20 g/L or more or
Required transfusion of 2 or more units of packed red blood cells or whole blood, or
Occurred in a critical site
Contributed to death.
CRNM bleeding was defined as bleeding that did not meet the criteria for major bleeding but that, in routine clinical practice, would be considered relevant and not trivial by a patient and physician. Such bleeding satisfied a priori criteria defined by the ICAC, including:
Skin hematoma
Epistaxis that lasted for longer than 5 minutes, was repetitive, or led to an intervention
Hematuria that was macroscopic and either spontaneous or lasted for longer than 24 hours after instrumentation of the urogenital tract
Any other bleeding type that was considered to have clinical consequences.</description>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O2" value="1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O3" value="1" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O4" value="4" lower_limit="3.5" upper_limit="29.0"/>
                    <measurement group_id="O5" value="2">No statistical analyses were conducted for Cohort 2.</measurement>
                    <measurement group_id="O6" value="3">No statistical analyses were conducted for Cohort 2.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Placebo</title>
          <description>Participants received placebo tablets once daily</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1: Apixaban, 5 mg</title>
          <description>Participants received apixaban as tablet, 5 mg, once daily</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1: Apixaban, 10 mg</title>
          <description>Participants received apixaban as tablet, 10 mg, once daily</description>
        </group>
        <group group_id="E4">
          <title>Cohort 1: Apixaban, 20 mg</title>
          <description>Participants received apixaban as tablet, 20 mg, once daily</description>
        </group>
        <group group_id="E5">
          <title>Cohort 2: Placebo</title>
          <description>Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.</description>
        </group>
        <group group_id="E6">
          <title>Cohort : Apixaban, 5 mg</title>
          <description>:Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal tract hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

